George et al., 2017 - Google Patents
The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neuronsGeorge et al., 2017
View HTML- Document ID
- 575263917346834697
- Author
- George C
- Gontier G
- Lacube P
- François J
- Holzenberger M
- Aïd S
- Publication year
- Publication venue
- Brain
External Links
Snippet
Seminal studies using post-mortem brains of patients with Alzheimer's disease evidenced aberrant insulin-like growth factor 1 receptor (IGF1R) signalling. Addressing causality, work in animal models recently demonstrated that long-term suppression of IGF1R signalling …
- 206010001897 Alzheimer's disease 0 title abstract description 164
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
Publication | Publication Date | Title |
---|---|---|
George et al. | The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons | |
Luo et al. | Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model | |
Stroo et al. | Cellular regulation of amyloid formation in aging and disease | |
Shilling et al. | Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis | |
Xia et al. | C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease | |
Hung et al. | PIKFYVE inhibition mitigates disease in models of diverse forms of ALS | |
Arreola et al. | Microglial dyshomeostasis drives perineuronal net and synaptic loss in a CSF1R+/− mouse model of ALSP, which can be rescued via CSF1R inhibitors | |
Ricobaraza et al. | Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease | |
Su et al. | PGC− 1α promoter methylation in Parkinson’s disease | |
Chen et al. | CREB binding protein is required for both short-term and long-term memory formation | |
Zhou et al. | The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease | |
Decressac et al. | α-Synuclein–induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons | |
Chopra et al. | Neurobiological aspects of Alzheimer's disease | |
Kandimalla et al. | A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic Tau mouse model of Alzheimer disease | |
Yao et al. | A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer’s disease pathologies | |
Eleuteri et al. | VPS35-based approach: a potential innovative treatment in Parkinson's disease | |
Habif et al. | Early long-term memory impairment and changes in the expression of synaptic plasticity-associated genes, in the McGill-R-Thy1-APP rat model of alzheimer's-like brain amyloidosis | |
Teravskis et al. | The accumulation of tau in postsynaptic structures: a common feature in multiple neurodegenerative diseases? | |
Owona et al. | Protective effects of forskolin on behavioral deficits and neuropathological changes in a mouse model of cerebral amyloidosis | |
Vijayan et al. | A partial reduction of VDAC1 enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model | |
Ishida et al. | Dorsal telencephalon-specific Nprl2-and Nprl3-knockout mice: novel mouse models for GATORopathy | |
Carter et al. | Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice | |
Li et al. | Inhibition of circ_0004381 improves cognitive function via miR-647/PSEN1 axis in an Alzheimer disease mouse model | |
Ma et al. | MacroH2A1. 2 deficiency leads to neural stem cell differentiation defects and autism‐like behaviors | |
Charif et al. | Protein synthesis modulation as a therapeutic approach for amyotrophic lateral sclerosis and frontotemporal dementia |